A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Summary

Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.

Timeline

Start

2008-01

Primary completion

2010-10

Completion

2010-10

Drugs

Indications